Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

BIBN-4096BS is a functionally selective CGRP receptor antagonist with potential in migraine Rx

July 2, 2001

E.C. approves Actiq via mutual recognition procedure

June 29, 2001

Patient enrollment completed in phase II trial of Axonyx's phenserine

June 29, 2001

Theratechnologies begins second phase II trial in sleep disorders; phase IIa results promising

June 29, 2001

FDA approves new formulation of Reminyl

June 29, 2001

Several related series of compounds identified at Merck as NMDA antagonists

June 28, 2001

Boehringer Ingelheim claims new CRGP antagonists and uses thereof

June 28, 2001

NCX-701 shows good bioavailability and safety in phase I

June 28, 2001

Japanese regulatory agency approves Allergan's Botox for cervical dystonia

June 28, 2001

Available for licensing from the NIH: novel inhibitors of p53

June 28, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...